Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Water Vapor Ablation for Grade Group 3 Prostate Cancer

NCT: NCT07652164 · NOT_YET_RECRUITING

NCT IDNCT07652164
StatusNOT_YET_RECRUITING
Start Date2026-08-31
Completion2028-09
SponsorFrancis Medical Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer. Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.

Frequently Asked Questions

What is Water Vapor Ablation for Grade Group 3 Prostate Cancer?

Water Vapor Ablation for Grade Group 3 Prostate Cancer is a clinical trial registered under NCT07652164. Current status: NOT_YET_RECRUITING.

What is the status of NCT07652164?

The current status of NCT07652164 (Water Vapor Ablation for Grade Group 3 Prostate Cancer) is: NOT_YET_RECRUITING.

When did Water Vapor Ablation for Grade Group 3 Prostate Cancer start?

Water Vapor Ablation for Grade Group 3 Prostate Cancer started on 2026-08-31.

Related Devices

K252388Vanquish Water Vapor Ablation DeviceFrancis Medical, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑